FBR’s Thomas Curran and Mark Kelley contend that Halliburton (HAL) and Baker Hughes (BHI) will need General Electric’s (GE) help if their merger–blocked yesterday by the Department of Justice–is to succeed:
Confirming the past week’s media reports, the U.S. Department of Justice (DOJ) announced yesterday, April 6, that it will sue to block the Halliburton-Baker Hughes merger. Based on our initial take, the crux of the DOJ’s objection is that Halliburton’s proposal does not create an adequate replacement for Baker Hughes. In an immediate press release,Halliburton replied that the two companies will “vigorously contest” the DOJ’s case; and, as both stocks rose in an oil price surgefueled group rally, the spread actually narrowed modestly. We suspect the spread’s move from $18.17 (implied gross return of 46.2%) to $16.98 (39.7%) reflected surprise by some thatHalliburton believes it still has a case. Cognizant of the now much lower odds of closing, we still like BHI’s risk/reward here: Should the deal fail, it will benefit from the $3.5B breakup fee, with the ability to fully implement restructuring initiatives that have bee n constrained by the merger agreement ($100M in 4Q15, or 300 bps of margin) and a spreading perception that it is back in play; should the deal succeed, the stock will deliver a 40% return, all else constant, within three to four months…
top 10 stocks to invest in: Aquinox Pharmaceuticals, Inc.(AQXP)
- [By Lee Jackson]
The Baker Brothers biotech hedge fund bought a block of 398,062 shares of Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) last week. At a per-shareprice of $17.18, the total for the trade came to$6,836,813.
top 10 stocks to invest in: (SMPQY)
- [By SEEKINGALPHA.COM]
We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ:ENDP), Sun Pharmaceutical Industries (OTC:SMPQY), Taro Pharmaceutical Industries Ltd. (NYSE:TARO), and Mayne (OTCPK:MAYNF). This shows that generics are not immune from criticism and price discussions. However, in our opinion, they are safer because they might be the solution to the high-price problem.
top 10 stocks to invest in: Take-Two Interactive Software, Inc.(TTWO)
- [By Lee Jackson]
Take-Two Interactive Software Inc. (NASDAQ: TTWO) saw the CFO at the video gaming company shedding shares this past week. Lainie Goldstein sold 56,167 shares at prices that ranged from $49.27 to $50.01. The total for the sale was posted at $3 million. The stocktraded on Friday at $47.90, so a well-timed sale indeed.
- [By Emily Stewart]
Paulson purchased one million shares of Take-Two Interactive Software (TTWO) last quarter. As of the end of the period, the stake is worth $37.9 million.
Take-Two Interactive is a developer, marketer and publisher of interactive entertainment for consumers around the globe. The company develops and publishes products through its two wholly owned labels: Rockstar Games and 2K. It has a $3.6 billion market cap and trades at a P/E of 165.16.
top 10 stocks to invest in: Shutterfly Inc.(SFLY)
- [By Chris Lange]
When Shutterfly Inc. (NASDAQ: SFLY) released its fourth-quarter earnings report after the markets closed on Wednesday, the company said it had $2.63 in earnings per share (EPS) and $561.2 million in revenue. The consensus estimates had called for $2.84 in EPS and revenue of $586.4 million. In the same period of last year, it posted EPS of $3.57 and $548.1 million in revenue.
top 10 stocks to invest in: Tobira Therapeutics, Inc.(TBRA)
- [By Benzinga News Desk]
Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.